BioHarvest Clears Breakeven on Q2 Numbers
BioHarvest Sciences Inc. (NASDAQ: BHST) shares began the day and the week slightly in the positive. The Israeli-based firm, a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.
All figures are in U.S. dollars unless stated otherwise.
Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points year-over-year.
Total U.S. active VINIA® users now 65,000, with >$60 million of cumulative revenue realized since USA launch in May 2021.
Business delivering balanced growth, with new products representing ~20% of growth and the core VINIA capsule business driving ~80% of growth.
Core capsule business grew by 28% with new products increasing by 100%.
Secured a new Stage 1 CDMO contract to develop a plant-based fragrance compound, derived from a plant that is under significant threat due to over-harvesting and habitat loss.
Announced first CDMO project to reach Stage 2 with completion of Stage 1 development for the CDMO contract with a NASDAQ-listed pharmaceutical company with an approved drug, successfully validating the botanical synthesis platform for a variety of molecule types.
BHST shares took on four cents to $8.80.
